Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1034842 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $39.07Day +1.48%Mkt cap $723MP/E (FY) 2.0×1Y +96.3%Off 52W high −24.9%Vol (1Y) 70.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,293 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.1% of sh out |
| Days to cover7.9d |
| 13F net flow (QoQ)+1.61% |
| Top-10 13F concentration51.4% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)2.0× |
| Sales (TTM)$299.8M |
| Earnings (TTM)$364.2M |
| ROE185.9% |
| Net margin124.7% |
| ROIC91.3% |
| Debt / equity0.13× |
| Total debt / EBITDA0.41× |
| Sales growth 3Y34.8% |
| YTD−8.8% |
| 1Y+96.3% |
| 3Y+183.1% |
| 5Y−4.5% |
| 10Y+70.6% |
| Since incept. (ann.)−7.8% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)70.6% |
| Ann. volatility (3Y)74.0% |
| Sharpe (1Y)1.30 |
| Sharpe (3Y)0.84 |
| Max drawdown (1Y)−50.1% |
| Max drawdown (3Y)−50.8% |
| Beta (3Y vs SPY)3.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 1.8M | $48M | 9.58% | +6.3% |
| ARMISTICE CAPITAL, LLC | 1.3M | $35M | 6.93% | +53.1% |
| STATE STREET CORP | 1.1M | $30M | 6.06% | +2.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 764,193 | $21M | 4.14% | new |
| ACADIAN ASSET MANAGEMENT LLC | 666,426 | $18M | 3.61% | +35.0% |
| LSV ASSET MANAGEMENT | 601,507 | $16M | 3.26% | +10.5% |
| MARSHALL WACE, LLP | 598,378 | $16M | 3.24% | −2.5% |
| AMERICAN CENTURY COMPANIES INC | 544,431 | $15M | 2.95% | +113.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | $0.44 | −30.2% | $58.8M | +10.3% |
| 2025-12-31 | 2026-03-03 | — | — | $69.8M | +21.2% |
| 2025-09-30 | 2025-11-04 | $1.46 | +108.6% | $69.5M | +25.6% |
| 2025-06-30 | 2025-08-05 | $3.28 | — | $101.7M | +176.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
